Contents of the journal : Т. 15, №2 (58)
A case from practice
Clinical Case of Laparoscopic Simultaneous Resection of the Dorsoventral Segment of the Liver and Transverse Colon ResectionAuthors: Burlaka A. Skyba V. Zemskov S. Mykytyuk A.... Т. 15, №2 (58)
Anesthetic care of a patient with recessive-dystrophic epidermolysis bullosa: a clinical case and practical recommendationsAuthors: Pochynok O.O. Lisnyy I.I. Ostafiychuk V.V. Т. 15, №2 (58)
Original Articles
Retrospective analysis of radical treatment of patients with stage III–IV larynpharyngetal cancerAuthors: Mykhailiuk P.I. Hirna H.A. Kostyshyn I.D. Tsybran S.S.... Т. 15, №2 (58)
Experience of using brentuximab vedotin in combination with chemotherapy for stage IV Hodgkin lymphoma in UkraineAuthors: Kryachok I.A. Titorenko I.B. Moroz Yu.V. Aleksyk O.M.... Т. 15, №2 (58)
Review Articles
Peritoneal carcinomatosis from gastric cancer treatment perspectives. A narrative reviewAuthors: Pepenin M.O. Kondratskyi Y.M. Dobrzhanskyi O.Y. Kolesnyk A.V.... Т. 15, №2 (58)
Modern approaches to the treatment of advanced ovarian cancer in the 1st line therapy (PAOLA-1 study) and recurrent ovarian cancer regardless of the presence of BRCA mutations, as well as modern cytoreductive approaches (based on materials from the ESGO 2025 Congress)
Prognostic factors for successful discontinuation of tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemiaAuthors: Tomashevska N.Y. Kotlyarchuk K.B. Korolchuk O.S. Boyko O.I.... Т. 15, №2 (58)
Management strategy for gastrointestinal stromal tumors (GIST): current status and future perspectivesAuthors: Kondratskyi Yu.M. Koval N.O. Kolesnyk A.V. Kozak E.O.... Т. 15, №2 (58)
Possibilities of modern visualization methods in planning radiation therapy in patients with cervical cancerAuthors: Ivankova V.S. Domina E.A. Khrulenko T.V. Baranovska L.M.... Т. 15, №2 (58)
Drugs used as radiosensitizers: clinical and pharmaceutical aspects and prospects (literature review)Authors: Andrushchenko I.V. Afanasieva I.O. Т. 15, №2 (58)
KEYTRUDA (pembrolizumab): expanding opportunities in the treatment of resectable non-small cell lung cancer
